Furthermore, in the studies focusing on the investigation of Nrf2 activators in FRDA models, it was seen that different compounds induced variable sets of Nrf2 downstream genes and had different effects on frataxin levels, which were dependent on the cell type (model) evaluated. The gene discussed is NFE2L2; the disease is Friedreich ataxia.